Heart Failure
Similar efficacy, lower adverse event risk with lower doses of pioglitazone
Both 15 mg and 30 mg pioglitazone doses have similar efficacy as 45 mg for preventing new-onset diabetes, stroke and myocardial infarction but with lower risk for adverse events, according to study findings.
REDUCE LAP-HF II
Interarterial shunt device (IASD, Corvia Medical) vs. sham procedure in patients with HF with preserved ejection fraction.
New cancer diagnosis associated with risk for fatal, nonfatal cardiovascular events
New cancer diagnosis appeared associated with increased risk for cardiovascular death, as well as incident heart failure, stroke or pulmonary embolism, according to a retrospective cohort study published in JACC: CardioOncology.
Novel collaborative care program reduces HF readmission rates
A chronic disease management pilot program designed to digitally connect health care providers and community-based agencies reduced HF readmission rates and improved communication among care team members, according to a case study.
In HFrEF, therapy in patients with frailty often not optimized despite high risk
In patients with HF with reduced ejection fraction, those with frailty had elevated risk for poor outcomes but less likelihood of being on optimal guideline-directed medical therapy, according to new data from the GUIDE-IT trial.
Chronic high-dose angiotensin receptor blocker use associated with cancer risk
Cumulative exposure to high-dose angiotensin receptor blockers was associated with excess risk for cancer, according to a meta-regression analysis published in PLOS One.
Top in cardiology: New empagliflozin indication, vegetable-rich diet
The FDA recently expanded the indication for the SGLT2 inhibitor empagliflozin to reduce the risk for cardiovascular death and heart failure hospitalization in adults with heart failure with reduced or preserved ejection fraction.
High levels of depressive symptoms tied to incident HF in Black women, not men
High depressive symptoms were associated with risk for incident HF among Black women, but not Black men, according to data published in the Journal of the American Heart Association.
FDA approves empagliflozin to reduce CV death, HF hospitalization in HFpEF
The FDA approved an expanded indication for the SGLT2 inhibitor empagliflozin to reduce the risk for CV death and HF hospitalization in adults with HF with reduced or preserved ejection fraction, according to an agency press release.
Hemodynamic sensor for management of HF receives expanded indication from FDA
Abbott announced its sensor providing hemodynamic-guided management of patients with HF has received an expanded indication from the FDA.